News and press releases

In the fourth quarter of the 2018/19 financial year, Coloplast delivered 8% organic revenue growth with reported revenue in DKK up by 9% to DKK 4,618m. This marks the company’s tenth consecutive quarter delivering 8% organic growth. Full-year organic revenue growth was also 8% with reported revenue in DKK up by 9% to DKK 17,939m. Full-year ROIC after tax and before special items was 48% against 44% last year.

“We are delivering a strong set of results with 8% organic growth and a 31% EBIT margin before special items. Expressed differently, we have helped make life easier for millions of people with intimate healthcare needs. We continue to take market share across all regions and across all business areas, and we continue to invest to drive both short-term growth as well as to build an even stronger and more competitive company for the medium and long term,” says Coloplast CEO Kristian Villumsen.

The business areas reported the following full-year organic growth rates: Ostomy Care 7%, Continence Care 8%, Interventional Urology 10% and Wound & Skin Care 8%.

Looking at sales by geographies, the European markets contributed 6% growth to full-year sales, Other developed markets, driven mainly by the USA, delivered 11% revenue growth, while Emerging Markets provided a 12% increase.

Full-year EBIT before special items amounted to DKK 5,556m, a 9% increase in DKK, corresponding to an EBIT-margin of 31%, which is in line with the company guidance and on par with 2017/18.

EBIT was impacted by a further provision of DKK 400m to cover potential settlements and costs in connection with the existing lawsuits in the United States alleging injury resulting from the use of transvaginal surgical mesh products. The additional provision is made because the remaining lawsuits are taking longer to resolve than initially expected, hence incurring higher costs. The company has not seen an increase in the inflow of new lawsuits.   

Interventional Urology remains core to the Coloplast mission and future value creation

An unconditional strategic review has concluded that Interventional Urology remains core to the Coloplast mission and future value creation. Coloplast is fully committed to further developing the business and providing the investment and focus required.

“After completing a thorough review, we have firmly concluded that the Interventional Urology business is core to our mission, and that retaining the business is the right decision to deliver continued shareholder value creation. Fundamentally, we observe large, fast-growing markets and real unmet clinical needs representing long-term growth opportunities,” says Kristian Villumsen and continues:

"Today, the business delivers strong growth and profitability, which is a good outset from which to invest and develop the business further, to derive even greater long-term value.” 

Financial guidance 2019/20
In line with its long-term guidance Coloplast is guiding for 7-8% organic revenue growth and a reported growth in DKK of 7-8% in 2019/20.

The guidance includes the effects of a comprehensive healthcare reform in France, representing an average reduction in prices for Ostomy Care and Continence Care of ~9% as of 1 July 2019, and Wound Care of ~2% as of 1 June 2019. Coloplast has successfully mitigated half of the impact.
Coloplast expects an EBIT margin of ~31% at constant exchange rates with a reported EBIT margin of ~31% in DKK. The EBIT margin forecast reflects additional incremental investments of up to 2% of revenue for innovation, sales, and marketing purposes.

In the third quarter of its financial year, Coloplast delivered 8% organic revenue growth, and reported revenue in DKK was up by 9% to DKK 4,599 million. This is mainly due to a favourable development in USD against DKK. For the 9M 2018/19 reporting period, organic revenue growth was also 8%, while reported revenue in DKK was up by 9% to DKK 13,321 million.

“We see strong performance in Europe driven by all business areas, double-digit growth in the US, and improved momentum in Emerging Markets driven by solid performance in China. Finally, I would like to highlight our 8% organic growth, year to date, in our Wound Care business and our double-digit growth, year to date, in the Interventional Urology business,” says CEO Kristian Villumsen, Coloplast, and continues:

“We deliver solid growth rates across all business areas, driven by our product launches and commercial investments, and we continue to invest in commercial initiatives to drive future growth.”

Organic growth rates by business area in the third quarter were 8% in Ostomy Care, 7% in Continence Care, 10% in Interventional Urology, and 7% in Wound & Skin Care.

Looking at sales by geographies in the third quarter, the European markets contributed with 5% growth, Other developed markets delivered 12% revenue growth, and Emerging Markets provided a 14% increase.

EBIT amounted to DKK 4,077m for the first nine months, an 11% increase in DKK, corresponding to an EBIT margin of 31% against 30% last year. ROIC after tax before special items was 45% in the first nine months against 42% in the same period last year.

French price reform

Following a reimbursement review, the French Ministry of Health has published new classifications and prices within Ostomy Care, Continence Care, and Wound Care in France. For Coloplast, the price reform represents an average reduction in prices in France for Ostomy Care and Continence Care of ~9% as of 1 July 2019, and Wound Care of ~2% as of 1 June 2019.

Unchanged financial guidance for 2018/19
Coloplast continues to expect organic revenue growth of ~8% at constant exchange rates and a reported growth in DKK of ~9%.

Coloplast continues to expect an EBIT margin of 30-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK. 

Our bodies are different, and it is a challenge to create products to fit individual bodies. This is also the case when it comes to premature babies and kids. That is why Coloplast is proud to present two additional and customised SenSura® Mio ostomy care products, SenSura® Mio Baby and SenSura® Mio Kids. Coloplast now offers a full range of ostomy care products to fit everyone and every body profile.

While SenSura® Mio, SenSura® Mio Convex, and SenSura® Mio Concave are designed to fit the individual shapes of adults with regular, inward, and outward body profiles, SenSura® Mio Baby and SenSura® Mio Kids are designed and developed especially for babies and kids.

“While it is uncommon for babies and kids to undergo stoma surgery, we want to make sure those who do have the best possible products. Despite it being difficult to create a great fit for the littlest of users, our latest products do just that,” says CEO Kristian Villumsen, Coloplast.

"As a market leader, we are proud to offer innovative products like SenSura® Mio Baby and SenSura® Mio Kids, which helps these little ostomates live healthy lives and not be limited by their conditions,” says Mr. Villumsen.

New best practice guidelines by stoma care professionals

The SenSura® Mio Baby products aim to provide longer wear time, as especially premature babies have sensitive skin, which needs as much peace and quiet as possible.

The new products include a best practice guideline developed by pediatric stoma care nurses with solid experience with babies and kids living with a stoma.

Red Dot award winner

Both SenSura® Mio Baby and SenSura® Mio Kids have won the Red Dot Award: Product Design 2019. The 'Red Dot' is the award for high quality design, and the international jury grants this seal of quality to products that feature an innovative and outstanding design.

“With the star-shaped baseplate, SenSura® Mio Kids is designed specifically for children’s round bellies. It is exciting to see the innovative SenSura® Mio Baby and SenSura® Mio Kids products being recognised for its design. I believe that these products successfully combine functionality and design – this is design with a purpose,” says SVP of Global Marketing Rasmus Hannemann, Coloplast.

Learn more on: www.red-dot.org

• SenSura® Mio Baby and SenSura® Mio Kids will be launched in Coloplast’s key markets throughout 2019.
• Coloplast is the global market leader in ostomy care products, holding 35-40% of the market.
• Photos of SenSura® Mio Baby and SenSura® Mio Kids are available on https://www.coloplast.com/press/download-images/

Coloplast delivered 8% organic growth in the second quarter. Year to date organic growth was also 8% and reported revenue in Danish kroner was up by 9% to DKK 8,722m. This is mainly due to a positive development in USD against DKK, and currency developments increased revenue by 1% in the second quarter.

In the second quarter, the organic growth rates by business area were 6% in Ostomy Care, 9% in Continence Care, 10% in Interventional Urology, and 9% in Wound & Skin Care.

Looking at sales by geography in the second quarter, the European markets contributed with 6% growth, Other developed markets delivered 10% revenue growth, while Emerging Markets provided a 11% increase.

“We maintain solid growth rates across all geographical regions and business areas, and our organic revenue growth continues to be twice the market growth. I would like to highlight our strong performance in Europe driven by our product launches within Ostomy Care and Continence Care, SenSura® Mio Convex, SenSura® Mio Concave and SpeediCath® Flex, as well as our strong Wound Care performance driven by the Biatain® Silicone portfolio in Europe, particularly in the UK and France,” says CEO Kristian Villumsen, Coloplast. 

The incremental investments into innovation and sales and marketing initiatives of up to 2% of revenue that were initiated in Q1 are progressing according to plan.

EBIT amounted to DKK 2,639m for the first six months, a 10% increase in DKK, corresponding to an EBIT margin of 30% on par with the same period last year.


Important win in the US
Coloplast is the new primary ostomy supplier for Kindred at Home, a home health agency with more than 700 locations throughout 41 states. With an estimated market share of ~5%, Kindred at Home is the largest home health agency in the US.    

“The US market holds great potential for our company, and our ambition is to continue to take market share. Our aim is to deliver double digit growth in both Ostomy Care and Continence Care, while raising the standard of care and making sure patients have access to their preferred products. The contract with Kindred at Home is an important win for us,” says Mr Villumsen.

Financial guidance for 2018/19
Coloplast continues to expect organic revenue growth of ~8% at constant exchange rates and now a reported growth in DKK of ~9% from previously 8-9%.

Coloplast continues to expect an EBIT margin of 30%-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.

Capital expenditure is now expected to be DKK ~700m from previously DKK ~750m, and we continue to expect the effective tax rate to be ~23%.

As a result, FDA regulations require that all anterior transvaginal synthetic mesh products, including Coloplast’s Restorelle DirectFix Anterior device, can no longer be commercialized in the U.S., effective immediately. Coloplast will work with the FDA and other relevant authorities to ensure the orderly removal of these devices from customer inventories.

In accordance with the FDA guidance, Coloplast recommends that women who have received transvaginal mesh for the surgical repair of pelvic organ prolapse should continue with their annual and other routine check-ups and follow-up care. There is no need to take additional action if you are satisfied with your surgery and are not having any complications or symptoms. However, any patient with questions or concerns should speak to her healthcare provider. Please refer to the full statement on the  FDA website.

Coloplast is disappointed by the FDA decision to remove surgical transvaginal mesh as a treatment option for women suffering from pelvic organ prolapse. Coloplast has been committed to working with the FDA on the 522 clinical studies to document the long-term efficacy and safety of the products.

“Our mission at Coloplast is making life easier for people with intimate healthcare needs. Pelvic organ prolapses (POP) can be a painful, embarrassing, and a debilitating issue for the women who suffer from it. While mesh sales to treat POP in women account for approximately 0.2% of our global revenue, we firmly believe that patients and their physicians should have a choice of therapies. We are disappointed with the FDA’s decision because it reduces the treatment options for women with POP. We remain committed to providing alternative therapies.” says CEO Kristian Villumsen, Coloplast.

Coloplast has alternative solutions for the same type of products including tissue products as well as alternative procedures for pelvic organ prolapse. The FDA’s decision is limited to mesh for the transvaginal repair of pelvic organ prolapse and does not extend to mesh used to treat stress urinary incontinence.

Coloplast delivered 8% organic revenue growth in the first three months of the 2018/19 financial year, while reported growth in Danish kroner was up by 9% to DKK 4,321m. Currency developments reduced revenue by less than 1%, and revenue from acquisitions contributed 1%.

Organic growth rates by business area were 8% in Ostomy Care, 8% in Continence Care, 9% in Interventional Urology, and 11% in Wound & Skin Care.

Looking at sales by geography, the European markets contributed with 6% growth, Other developed markets delivered 10% revenue growth, while Emerging Markets provided a 14% increase.

“We maintain solid growth rates across all geographical regions and business areas. I would like to highlight our strong performance in Europe driven by new product launches and our Wound Care business delivering 10% organic growth driven by the Biatain® Silicone portfolio in UK and France. Our organic revenue growth is twice the market growth, and we maintain our guidance for 2018/19. In short, we are off to a good start to the financial year,” says newly appointed Coloplast CEO Kristian Villumsen. 

Investments in further growth
Coloplast continued its incremental investments in growth of up to 2% of revenue during the first quarter. Investments were made in innovation as well as sales and marketing initiatives across multiple markets and business areas.

In addition, Coloplast is expanding its SpeediCath® portfolio with the launch of SpeediCath® Navi. SpeediCath® Navi is a hydrophilic catheter designed specifically for Emerging Markets and it will be launched during 2019 and 2020.    

-        “As part of our investments in Emerging Markets, we’re proud to be able to offer a product developed specifically for catheter users in this region. Our aim is to raise the standard of care and to accommodate markets with lower reimbursement.  I’m confident that SpeediCath® Navi will make a big difference to our users, while giving Coloplast a strong competitive edge,” says Mr Villumsen.

Financial guidance for 2018/19
Coloplast continues to expect organic revenue growth of ~8% at constant exchange rates and a reported growth in DKK of 8-9%.

Coloplast continues to expect an EBIT margin of 30%-31% at constant exchange rates and a reported EBIT margin of ~31% in DKK.